The increasing demand for robust and reproducible analytical tools in vaccine manufacturing has highlighted critical limitations in the current supply of Research Use Only (RUO) antibodies. In the context of Varicella-Zoster Virus (VZV) vaccines, quality control (QC) assays rely heavily on antibody-based detection of viral antigens, including envelope glycoproteins. However, many commercially available antibodies lack traceability, batch-to-batch consistency, and detailed characterization.

Here, we describe the development and production strategy of high-quality monoclonal antibodies specifically designed for VZV vaccine QC applications. Emphasis is placed on reproducibility, defined production processes, and rigorous validation, addressing a key gap identified by major vaccine manufacturers.

Vaccines targeting Varicella-Zoster Virus remain critical in preventing varicella (chickenpox) and herpes zoster (shingles). Industrial production of these vaccines requires stringent quality control to ensure antigen integrity, potency, and consistency across batches.

A central component of QC assays is the use of antibodies directed against VZV antigens (e.g., glycoproteins such as gE, gB, gH). These antibodies are used in:

• ELISA-based antigen quantification
• Western blot identity testing
• Immunofluorescence assays
• Process monitoring and lot release

Despite their importance, the sourcing of these antibodies remains problematic.

Many antibodies currently used in vaccine QC workflows suffer from:

• Lack of traceability (unknown origin or hybridoma history)
• Poor batch-to-batch reproducibility
• Undefined production processes
• Insufficient validation data for industrial applications

This creates significant risk in regulated environments, even when reagents are formally classified as RUO. In practice, vaccine manufacturers require GMP-like robustness, even for non-GMP reagents.

There is increasing evidence that major vaccine producers are actively seeking reliable, well-characterized antibody sources to secure their QC pipelines.

SYnAbs has developed a structured approach to address these challenges, combining hybridoma expertise with modern recombinant strategies.

• Documented antigen design and immunization protocols
• Full hybridoma lineage tracking
• Sequence recovery (VH/VL) when applicable

• Transition from hybridoma to recombinant expression when needed
• Defined upstream and downstream processes
• Scalable production compatible with industrial demand

Antibodies are characterized using:

• ELISA (antigen specificity and sensitivity)
• Western blot (protein recognition under denaturing conditions)
• Immunofluorescence (cell-based detection of VZV infection)

Focus is placed on functional performance in QC-relevant assays, not just binding.

SYnAbs antibodies are designed to support key QC steps, including:

• Antigen quantification in bulk and final product
• Identity testing of viral components
• Monitoring of production consistency
• Support for assay development and validation

Particular attention is given to VZV glycoprotein detection, a critical marker for vaccine potency and integrity.

Even in RUO classification, industrial users—particularly large vaccine manufacturers—require:

• Long-term supply security
• Reproducibility across lots
• Technical documentation and support
• Transparency in reagent origin

SYnAbs positions its antibodies as “RUO with industrial-grade reliability”, bridging the gap between research reagents and regulated QC tools.

The reliability of antibody-based assays is a critical determinant of vaccine quality control performance. In the VZV field, the current lack of traceable and reproducible RUO antibodies represents a significant vulnerability for manufacturers.

By combining traceability, controlled production, and application-driven validation, SYnAbs provides a new generation of antibodies aligned with industrial QC requirements. This approach supports more robust, reproducible, and secure vaccine manufacturing processes.